Off-label use of recombinant factor VIIa in patients following bone marrow transplantation

@article{Blatt2001OfflabelUO,
  title={Off-label use of recombinant factor VIIa in patients following bone marrow transplantation},
  author={Julie Blatt and S Gold and J A Wiley and P B Monahan and H. Cooper and Donald Harvey},
  journal={Bone Marrow Transplantation},
  year={2001},
  volume={28},
  pages={405-407}
}
Recombinant factor VIIa (rFVIIa, NovoSeven) is FDA-approved for the treatment of bleeding in patients with hemophilia A/B with inhibitors. A growing literature suggests that there may be expanded indications for the use of NovoSeven in patients with significant bleeding who do not have a known factor deficiency. Severe bleeding refractory to standard hematologic or hemostatic support is common in patients undergoing bone marrow transplantation (BMT). We review our experience with rFVIIa in… CONTINUE READING
27 Citations
7 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

References

Publications referenced by this paper.
Showing 1-7 of 7 references

Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery

  • M Al Douri, T Shafi, D Al Khudairi
  • Blood Coag Fibrinol
  • 2000

Recombinant Factor VIIa in congenital platelet bleeding disorders

  • M-C Poon, O Katsarou, A Huth-Kuehne
  • Proc Am Soc Hematol
  • 2000

Similar Papers

Loading similar papers…